Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

2025-04-22 07:40:22 ET

Summary

• We initiate a Hold rating for Celldex Therapeutics due to uncertainties surrounding barzolvolimab's mid-2025 data readouts and potential market positioning challenges.
• Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects.
• Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting downward pressure on valuation.
• Investment risks include trial failures, commercial uptake challenges, resource-intensive commercialization, potential side effects, and broader macroeconomic factors affecting funding and share price.

Summary

We initiate coverage on Celldex Therapeutics ( CLDX ) with a Hold recommendation. We believe that barzolvolimab, its lead pipeline candidate, represents an interesting approach to treating chronic spontaneous urticaria, but considerable clinical and commercial uncertainties remain....

Read the full article on Seeking Alpha

For further details see: